Latest Commercial Strategy News

Page 4 of 22
Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.
Ada Torres
Ada Torres
9 July 2026
Proteomics International has won a key US patent for its PromarkerEndo blood test, bolstering its commercial foothold in the world’s largest healthcare market. The patented technology offers a non-invasive, accurate diagnosis of endometriosis, a condition that currently takes years to detect.
Ada Torres
Ada Torres
8 July 2026
ION Video Limited (ASX: IOV) reported its first-ever positive operating cash flow of $179,847 for the June quarter, eliminated $2.65 million of debt through Convertible Note conversion, and expanded its patent portfolio to five families while advancing its Virtual Video platform technology.
Sophie Babbage
Sophie Babbage
7 July 2026
Dataworks Group has arranged a $1.5 million unsecured working capital facility with a three-month term and 18% interest, aiming to strengthen liquidity and support ongoing and new commercial contracts without diluting equity.
Sophie Babbage
Sophie Babbage
3 July 2026
Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.
Ada Torres
Ada Torres
2 July 2026
Imricor Medical Systems expands its US market reach with FDA 510(k) clearances for pediatric use of its NorthStar system and Vision-MR Diagnostic Catheter, enabling radiation-free cardiac catheterisations for children.
Ada Torres
Ada Torres
2 July 2026
Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.
Ada Torres
Ada Torres
1 July 2026
Memphasys has secured $1.2 million through a share placement to support the global expansion and manufacturing scale-up of its Felix™ sperm selection system. The company also extended a major convertible note, reinforcing financial flexibility amid growing international contracts.
Ada Torres
Ada Torres
18 June 2026
Environmental Clean Technologies (ASX: ECT) has completed a pilot Rapid Electrothermal Mineralisation system that delivers 18 times the power of its lab prototype, enabling additive-free, in-situ PFAS destruction and targeting a field demonstration in H2 2026.
Maxwell Dee
Maxwell Dee
15 June 2026
Temas Resources is on track to fully commission its Ontario metallurgical lab by July 2026, initiating large-scale testing of La Blache project material to refine its proprietary RCL technology and support commercialization.
Maxwell Dee
Maxwell Dee
12 June 2026
ReNerve has appointed J4 Biologics as a second manufacturer for its Empliq range to meet growing hospital approvals and market demand, strengthening its supply chain and scaling production capacity.
Ada Torres
Ada Torres
11 June 2026
Optiscan Imaging has reached the halfway recruitment milestone in its first in-human breast cancer study, advancing its regulatory and commercial ambitions with promising clinical data and expanded trial sites.
Ada Torres
Ada Torres
4 June 2026

Browse the archive

Full archive